IP Library Granted Patent US 7,078,197
Granted Patent B2
US 7,078,197 · App. 10/208,357 · Granted Jul 18, 2006

Peptide acceptor ligation methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,197
App. No.
10/208,357
Granted
Jul 18, 2006
Kind
B2
Abstract

Described herein are methods and reagents for the ligation of a peptide acceptor to an RNA, as well as the RNA-peptide acceptor products.

Claims (11)

1. A method of affixing a peptide acceptor to an RNA molecule, said method comprising: (a) providing an RNA molecule having a 3′ sequence which forms a hairpin structure; (b) providing a peptide acceptor covalently bonded to a nucleic acid linker molecule; and (c) hybridizing said RNA molecule to said nucleic acid linker molecule under conditions which allow covalent bond formation to occur between said peptide acceptor and said RNA molecule.

2. The method of claim 1 , wherein said covalent bond formation is catalyzed by T4 DNA ligase.

3. A method of affixing a peptide acceptor to an RNA molecule, comprising: (a) providing an RNA molecule; (b) providing a peptide acceptor covalently bonded to a linker molecule, wherein the 5′ sequence of said linker molecule forms a nucleic acid hairpin structure; and (c) hybridizing said RNA molecule to said linker molecule under conditions which allow covalent bond formation to occur between said peptide acceptor and said RNA molecule.

4. The method of claim 3 , wherein said covalent bond formation is catalyzed by T4 DNA ligase.

5. The method of claim 3 , wherein said RNA molecule comprises a translation initiation sequence and a start codon operably linked to a protein coding sequence.

6. The method of claim 3 , wherein said peptide acceptor is puromycin.

7. The method of claim 3 , wherein said linker molecule further comprises non-nucleotide moieties.

8. The method of claim 7 , wherein said non-nucleotide moieties comprises triethylene glycol spacers.

9. The method of claim 7 , wherein said non-nucleotide moieties comprises 2′-OMe-RNA phosphoramidites.

10. The method of claim 3 , wherein said RNA or said linker contains an affinity purification sequence and said method further comprises purifying said RNA.

11. The method of claim 10 , wherein said affinity purification sequence comprises a poly (A) sequence.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2009
From: ADNEXUS, A BRISTOL-MYERS SQUIBB R&D COMPANY
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 023056/0255 →
CHANGE OF NAME Recorded Aug 11, 2008
From: ADNEXUS, A BMS R&D COMPANY
To: ADNEXUS, A BRISTOL-MYERS SQUIBB R&D COMPANY
Reel/Frame 021371/0781 →
MERGER Recorded Aug 11, 2008
From: ADNEXUS THERAPEUTICS, INC.
To: ADNEXUS, A BMS R&D COMPANY
Reel/Frame 021428/0782 →
CHANGE OF NAME Recorded Aug 13, 2007
From: COMPOUND THERAPEUTICES INC.
To: ADNEXUS THERAPEUTICS, INC.
Reel/Frame 019679/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2007
From: PHYLOS, INC.
To: COMPOUND THERAPEUTICS INC.
Reel/Frame 019679/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2007
From: KURZ, MARKUS; LOHSE, PETER; WAGNER, RICHARD W.
To: PHYLOS, INC.
Reel/Frame 019679/0864 →
CHANGE OF NAME Recorded Aug 7, 2006
From: COMPOUND THERAPEUTICS, INC.
To: ADNEXUS THERAPEUTICS, INC.
Reel/Frame 018061/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2004
From: PHYLOS, INC.
To: COMPOUND THERAPEUTICS, INC.
Reel/Frame 014313/0534 →